Skip to main content
Top
Published in: Hepatology International 2/2013

01-06-2013 | Review Article

Autoimmune acute liver failure: an emerging etiology for intractable acute liver failure

Authors: Keiichi Fujiwara, Shin Yasui, Osamu Yokosuka

Published in: Hepatology International | Issue 2/2013

Login to get access

Abstract

Diagnosis of acute onset autoimmune hepatitis (AIH) is the most challenging task because of atypical clinicopathological features. We examined the nature of acute onset AIH consisting of nonsevere, severe, and fulminant AIH based on our published data and other published papers, and propose how to diagnose and treat this intractable hepatitis. We analyzed clinical, biochemical, immunological, radiological, and histological features of acute onset AIH. Thirty percent of fulminant hepatitis was due to AIH and autoimmune acute liver failure (ALF) was not rare. The important characteristic of acute onset AIH is its histological, radiological, and clinical heterogeneity. Sometimes acute onset AIH develops into ALF in a sub-acute clinical course without appropriate diagnosis and treatment, and becomes resistant to immunosuppressive therapy and has poor prognosis. Unenhanced computed tomography (CT) often shows heterogeneous hypoattenuation in autoimmune ALF. The revised original scoring system (1999) performed better in patients with acute onset AIH than the simplified scoring system (2008). Liver regeneration from periportal progenitor cells to mature hepatocytes was impaired in ALF, resulting in resistance to immunosuppressive therapy. Precise histological evaluation (the presence of centrilobular necrosis/collapse) along with the revised original scoring system and CT findings of heterogeneous hypoattenuation after systematic exclusion of other causes 36 plays an important role in the diagnosis. The most important strategy for autoimmune ALF is to diagnose and treat acute onset AIH before its development into ALF. Liver transplantation should be considered before the occurrence of infectious complications in the case of fulminant liver failure.
Literature
1.
go back to reference Fujiwara K, Mochida S, Matsui A, Intractable Liver Diseases Study Group of Japan, et al. Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res. 2008;38:646–657CrossRef Fujiwara K, Mochida S, Matsui A, Intractable Liver Diseases Study Group of Japan, et al. Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res. 2008;38:646–657CrossRef
2.
go back to reference Lee WM, Squires RH Jr, Nyberg SL, Doo E, Hoofnagle JH. Acute liver failure: summary of a workshop. Hepatology. 2008;47:1401–1415CrossRef Lee WM, Squires RH Jr, Nyberg SL, Doo E, Hoofnagle JH. Acute liver failure: summary of a workshop. Hepatology. 2008;47:1401–1415CrossRef
3.
go back to reference Ichai P, Samuel D. Etiology and prognosis of fulminant hepatitis in adults. Liver Transpl. 2008;14:S67–S79CrossRef Ichai P, Samuel D. Etiology and prognosis of fulminant hepatitis in adults. Liver Transpl. 2008;14:S67–S79CrossRef
4.
go back to reference Fujiwara K, Yokosuka O, Kojima H, et al. Importance of adequate immunosuppressive therapy for the recovery of patients with “life-threatening” severe exacerbation of chronic hepatitis B. World J Gastroenterol. 2005;11:1109–1114CrossRef Fujiwara K, Yokosuka O, Kojima H, et al. Importance of adequate immunosuppressive therapy for the recovery of patients with “life-threatening” severe exacerbation of chronic hepatitis B. World J Gastroenterol. 2005;11:1109–1114CrossRef
5.
go back to reference Fujiwara K, Yasui S, Yonemitsu Y, et al. Efficacy of combination therapy of antiviral and immunosuppressive drugs for the treatment of severe acute exacerbation of chronic hepatitis B. J Gastroenterol. 2008;43:711–719CrossRef Fujiwara K, Yasui S, Yonemitsu Y, et al. Efficacy of combination therapy of antiviral and immunosuppressive drugs for the treatment of severe acute exacerbation of chronic hepatitis B. J Gastroenterol. 2008;43:711–719CrossRef
6.
go back to reference Fujiwara K, Yasui S, Okitsu K, et al. The requirement for a sufficient period of corticosteroid treatment in combination with nucleoside analogue for severe acute exacerbation of chronic hepatitis B. J Gastroenterol. 2010;45:1255–1262CrossRef Fujiwara K, Yasui S, Okitsu K, et al. The requirement for a sufficient period of corticosteroid treatment in combination with nucleoside analogue for severe acute exacerbation of chronic hepatitis B. J Gastroenterol. 2010;45:1255–1262CrossRef
7.
go back to reference Czaja AJ. Autoimmune hepatitis: evolving concepts and treatment strategies. Dig Dis Sci. 1995;40:435–456CrossRef Czaja AJ. Autoimmune hepatitis: evolving concepts and treatment strategies. Dig Dis Sci. 1995;40:435–456CrossRef
8.
go back to reference Czaja AJ, Carpenter HA. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology. 1993;105:1824–1832CrossRef Czaja AJ, Carpenter HA. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology. 1993;105:1824–1832CrossRef
9.
go back to reference Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–938CrossRef Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–938CrossRef
10.
go back to reference Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol. 1994;21:866–871CrossRef Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol. 1994;21:866–871CrossRef
11.
go back to reference Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology. 1983;85:713–717PubMed Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology. 1983;85:713–717PubMed
12.
go back to reference Kessler WR, Cummings OW, Eckert G, et al. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol. 2004;2:625–631CrossRef Kessler WR, Cummings OW, Eckert G, et al. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol. 2004;2:625–631CrossRef
13.
go back to reference Miyake Y, Iwasaki Y, Terada R, et al. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment Pharmacol Ther. 2006;23:1347–1353CrossRef Miyake Y, Iwasaki Y, Terada R, et al. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment Pharmacol Ther. 2006;23:1347–1353CrossRef
14.
go back to reference Porta G, Gayotto LC, Alvarez F. Anti-liver-kidney microsome antibody-positive autoimmune hepatitis presenting as fulminant liver failure. J Ped Gastroenterol Nutrition. 1990;11:138–140CrossRef Porta G, Gayotto LC, Alvarez F. Anti-liver-kidney microsome antibody-positive autoimmune hepatitis presenting as fulminant liver failure. J Ped Gastroenterol Nutrition. 1990;11:138–140CrossRef
15.
go back to reference Abe M, Mashiba T, Zeniya M, Autoimmune Hepatitis Study Group—Subgroup of the Intractable Hepato-Biliary Disease Study Group in Japan, et al. Present status of autoimmune hepatitis in Japan: a nationwide survey. J Gastroenterol. 2011;46:1136–1141CrossRef Abe M, Mashiba T, Zeniya M, Autoimmune Hepatitis Study Group—Subgroup of the Intractable Hepato-Biliary Disease Study Group in Japan, et al. Present status of autoimmune hepatitis in Japan: a nationwide survey. J Gastroenterol. 2011;46:1136–1141CrossRef
16.
go back to reference Onji M, Autoimmune Hepatitis Study Group. Proposal of autoimmune hepatitis presenting with acute hepatitis, severe hepatitis and acute liver failure. Hepatol Res. 2011;41:497CrossRef Onji M, Autoimmune Hepatitis Study Group. Proposal of autoimmune hepatitis presenting with acute hepatitis, severe hepatitis and acute liver failure. Hepatol Res. 2011;41:497CrossRef
17.
go back to reference Abe M, Onji M, Kawai-Ninomiya K, et al. Clinicopathologic features of the severe form of acute type 1 autoimmune hepatitis. Clin Gastroenterol Hepatol. 2007;5:255–258CrossRef Abe M, Onji M, Kawai-Ninomiya K, et al. Clinicopathologic features of the severe form of acute type 1 autoimmune hepatitis. Clin Gastroenterol Hepatol. 2007;5:255–258CrossRef
18.
go back to reference Williams R, Wendon J. Indications for orthotopic liver transplantation in fulminant liver failure. Hepatology. 1994;20:S5–S10CrossRef Williams R, Wendon J. Indications for orthotopic liver transplantation in fulminant liver failure. Hepatology. 1994;20:S5–S10CrossRef
19.
go back to reference Ostapowicz G, Fontana RJ, Schiødt FV, U.S. Acute Liver Failure Study Group, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947–954CrossRef Ostapowicz G, Fontana RJ, Schiødt FV, U.S. Acute Liver Failure Study Group, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947–954CrossRef
20.
go back to reference Fujiwara K, Yasui S, Tawada A, et al. Autoimmune fulminant liver failure in adults. Experience in a Japanese center. Hepatol Res. 2011;41:133–141CrossRef Fujiwara K, Yasui S, Tawada A, et al. Autoimmune fulminant liver failure in adults. Experience in a Japanese center. Hepatol Res. 2011;41:133–141CrossRef
21.
go back to reference Stravitz RT, Lefkowitch JH, Fontana RJ, Acute Liver Failure Study Group, et al. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology. 2011;53:517–526CrossRef Stravitz RT, Lefkowitch JH, Fontana RJ, Acute Liver Failure Study Group, et al. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology. 2011;53:517–526CrossRef
22.
go back to reference Fujiwara K, Yasui S, Yokosuka O. Efforts at making the diagnosis of acute onset autoimmune hepatitis. Hepatology. 2011;54:371–372CrossRef Fujiwara K, Yasui S, Yokosuka O. Efforts at making the diagnosis of acute onset autoimmune hepatitis. Hepatology. 2011;54:371–372CrossRef
23.
go back to reference Tokumoto Y, Onji M. Acute-onset autoimmune hepatitis. Intern Med. 2007;46:1–2CrossRef Tokumoto Y, Onji M. Acute-onset autoimmune hepatitis. Intern Med. 2007;46:1–2CrossRef
24.
go back to reference Singh R, Nair S, Farr G, Mason A, Perrillo R. Acute autoimmune hepatitis presenting with centrizonal liver disease: case report and review of the literature. Am J Gastroenterol. 2002;97:2670–2673CrossRef Singh R, Nair S, Farr G, Mason A, Perrillo R. Acute autoimmune hepatitis presenting with centrizonal liver disease: case report and review of the literature. Am J Gastroenterol. 2002;97:2670–2673CrossRef
25.
go back to reference Lefkowitch JH, Apfelbaum TF, Weinberg L, Forester G. Acute liver biopsy lesions early autoimmune (‘lupoid’) chronic active hepatitis. Liver. 1984;4:379–386CrossRef Lefkowitch JH, Apfelbaum TF, Weinberg L, Forester G. Acute liver biopsy lesions early autoimmune (‘lupoid’) chronic active hepatitis. Liver. 1984;4:379–386CrossRef
26.
go back to reference Abe M, Hiasa Y, Masumoto T, et al. Clinical characteristics of autoimmune hepatitis with histological feature of acute hepatitis. Hepatol Res. 2001;21:213–219CrossRef Abe M, Hiasa Y, Masumoto T, et al. Clinical characteristics of autoimmune hepatitis with histological feature of acute hepatitis. Hepatol Res. 2001;21:213–219CrossRef
27.
go back to reference Okano N, Yamamoto K, Sakaguchi K. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res. 2003;25:263–270CrossRef Okano N, Yamamoto K, Sakaguchi K. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res. 2003;25:263–270CrossRef
28.
go back to reference Misdraji J, Thiim M, Graeme-Cook FM. Autoimmune hepatitis with centrilobular necrosis. Am J Surg Pathol. 2004;28:471–478CrossRef Misdraji J, Thiim M, Graeme-Cook FM. Autoimmune hepatitis with centrilobular necrosis. Am J Surg Pathol. 2004;28:471–478CrossRef
29.
go back to reference Hofer H, Oesterreicher C, Wrba F, Ferenci P, Penner E. Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol. 2006;59:246–249CrossRef Hofer H, Oesterreicher C, Wrba F, Ferenci P, Penner E. Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol. 2006;59:246–249CrossRef
30.
go back to reference Fujiwara K, Fukuda Y, Yokosuka O. Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute onset autoimmune hepatitis. J Gastroenterol. 2008;43:951–958CrossRef Fujiwara K, Fukuda Y, Yokosuka O. Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute onset autoimmune hepatitis. J Gastroenterol. 2008;43:951–958CrossRef
31.
go back to reference Yasui S, Fujiwara K, Yonemitsu Y, et al. Clinicopathological features of severe and fulminant forms of autoimmune hepatitis. J Gastroenterol. 2011;46:378–390CrossRef Yasui S, Fujiwara K, Yonemitsu Y, et al. Clinicopathological features of severe and fulminant forms of autoimmune hepatitis. J Gastroenterol. 2011;46:378–390CrossRef
32.
go back to reference Iwai M, Jo M, Ishii M, Mori T, Harada Y. Comparison of clinical features and liver histology in acute and chronic autoimmune hepatitis. Hepatol Res. 2008;38:784–789CrossRef Iwai M, Jo M, Ishii M, Mori T, Harada Y. Comparison of clinical features and liver histology in acute and chronic autoimmune hepatitis. Hepatol Res. 2008;38:784–789CrossRef
33.
go back to reference Te HS, Koukoulis G, Ganger DR. Autoimmune hepatitis: a histological variant associated with prominent centrilobular necrosis. Gut. 1997;41:269–271CrossRef Te HS, Koukoulis G, Ganger DR. Autoimmune hepatitis: a histological variant associated with prominent centrilobular necrosis. Gut. 1997;41:269–271CrossRef
34.
go back to reference Pratt DS, Fawaz KA, Rabson A, Dellelis R, Kaplan MM. A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology. 1997;113:664–668CrossRef Pratt DS, Fawaz KA, Rabson A, Dellelis R, Kaplan MM. A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology. 1997;113:664–668CrossRef
35.
go back to reference Zen Y, Notsumata K, Tanaka N, Nakanuma Y. Hepatic centrilobular zonal necrosis with positive antinuclear antibody: a unique subtype or early disease of autoimmune hepatitis? Hum Pathol. 2007;38:1669–1675CrossRef Zen Y, Notsumata K, Tanaka N, Nakanuma Y. Hepatic centrilobular zonal necrosis with positive antinuclear antibody: a unique subtype or early disease of autoimmune hepatitis? Hum Pathol. 2007;38:1669–1675CrossRef
36.
go back to reference Burgart LJ, Batts KP, Ludwig J, Nikias GA, Czaja AJ. Recent onset autoimmune hepatitis. Biopsy findings and clinical correlations. Am J Surg Pathol. 1995;19:699–708CrossRef Burgart LJ, Batts KP, Ludwig J, Nikias GA, Czaja AJ. Recent onset autoimmune hepatitis. Biopsy findings and clinical correlations. Am J Surg Pathol. 1995;19:699–708CrossRef
37.
go back to reference Fujiwara K, Yasui S, Tawada A, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group criteria in acute onset autoimmune hepatitis. Liver Int. 2011;31:1013–1020CrossRef Fujiwara K, Yasui S, Tawada A, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group criteria in acute onset autoimmune hepatitis. Liver Int. 2011;31:1013–1020CrossRef
38.
go back to reference Johnson PJ, McFarlane IG. Meeting report: international autoimmune hepatitis group. Hepatology. 1993;18:998–1005CrossRef Johnson PJ, McFarlane IG. Meeting report: international autoimmune hepatitis group. Hepatology. 1993;18:998–1005CrossRef
39.
go back to reference Hennes EM, Zeniya M, Czaja AJ, International Autoimmune Hepatitis Group, et al. Simplified diagnostic criteria for autoimmune hepatitis. Hepatology. 2008;48:169–176CrossRef Hennes EM, Zeniya M, Czaja AJ, International Autoimmune Hepatitis Group, et al. Simplified diagnostic criteria for autoimmune hepatitis. Hepatology. 2008;48:169–176CrossRef
40.
go back to reference Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology. 2008;48:1540–1548CrossRef Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology. 2008;48:1540–1548CrossRef
41.
go back to reference Yeoman AD, Westbrook RH, Al-Chalabi T, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology. 2009;50:538–545CrossRef Yeoman AD, Westbrook RH, Al-Chalabi T, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology. 2009;50:538–545CrossRef
42.
go back to reference Murakami T, Baron RL, Peterson MS. Liver necrosis and regeneration after fulminant hepatitis: pathologic correlation with CT and MR findings. Radiology. 1996;198:239–242CrossRef Murakami T, Baron RL, Peterson MS. Liver necrosis and regeneration after fulminant hepatitis: pathologic correlation with CT and MR findings. Radiology. 1996;198:239–242CrossRef
43.
go back to reference Yasui S, Fujiwara K, Yokosuka O. Autoimmune fulminant hepatic failure in chronic hepatitis C during Peg-interferon-alpha 2b plus ribavirin treatment showing histological heterogeneity. Dig Liver Dis. 2011;43:666–667CrossRef Yasui S, Fujiwara K, Yokosuka O. Autoimmune fulminant hepatic failure in chronic hepatitis C during Peg-interferon-alpha 2b plus ribavirin treatment showing histological heterogeneity. Dig Liver Dis. 2011;43:666–667CrossRef
44.
go back to reference Yasui S, Fujiwara K, Okitsu K, et al. Importance of computed tomography imaging features for the diagnosis of autoimmune acute liver failure. Hepatol Res. 2012;42:42–50CrossRef Yasui S, Fujiwara K, Okitsu K, et al. Importance of computed tomography imaging features for the diagnosis of autoimmune acute liver failure. Hepatol Res. 2012;42:42–50CrossRef
45.
go back to reference Sell S. Heterogeneity and plasticity of hepatocyte lineage cells. Hepatology. 2001;33:738–750CrossRef Sell S. Heterogeneity and plasticity of hepatocyte lineage cells. Hepatology. 2001;33:738–750CrossRef
46.
go back to reference Eleazar JA, Memeo L, Jhang JS, et al. Progenitor cell expansion: an important source of hepatocyte regeneration in chronic hepatitis. J Hepatol. 2004;41:983–991CrossRef Eleazar JA, Memeo L, Jhang JS, et al. Progenitor cell expansion: an important source of hepatocyte regeneration in chronic hepatitis. J Hepatol. 2004;41:983–991CrossRef
47.
go back to reference Fujiwara K, Nakano M, Yasui S, et al. Advanced histology and impaired liver regeneration are associated with disease severity in acute onset autoimmune hepatitis. Histopathology. 2011;58:693–704CrossRef Fujiwara K, Nakano M, Yasui S, et al. Advanced histology and impaired liver regeneration are associated with disease severity in acute onset autoimmune hepatitis. Histopathology. 2011;58:693–704CrossRef
48.
go back to reference Manns MP, Czaja AJ, Gorham JD, American Association for the Study of Liver Diseases, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193–2213CrossRef Manns MP, Czaja AJ, Gorham JD, American Association for the Study of Liver Diseases, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193–2213CrossRef
49.
go back to reference Czaja AJ. Difficult treatment decisions in autoimmune hepatitis. World J Gastroenterol. 2010;16:934–947CrossRef Czaja AJ. Difficult treatment decisions in autoimmune hepatitis. World J Gastroenterol. 2010;16:934–947CrossRef
50.
go back to reference Ichai P, Duclos-Vallée JC, Guettier C, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl. 2007;13:996–1003CrossRef Ichai P, Duclos-Vallée JC, Guettier C, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl. 2007;13:996–1003CrossRef
51.
go back to reference Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation. Liver Transpl. 2007;13:953–955CrossRef Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation. Liver Transpl. 2007;13:953–955CrossRef
52.
go back to reference Yasui S, Fujiwara K, Tawada A, et al. Efficacy of intravenous glycyrrhizin in the early stage of acute onset autoimmune hepatitis. Dig Dis Sci. 2011;56:3638–3647CrossRef Yasui S, Fujiwara K, Tawada A, et al. Efficacy of intravenous glycyrrhizin in the early stage of acute onset autoimmune hepatitis. Dig Dis Sci. 2011;56:3638–3647CrossRef
Metadata
Title
Autoimmune acute liver failure: an emerging etiology for intractable acute liver failure
Authors
Keiichi Fujiwara
Shin Yasui
Osamu Yokosuka
Publication date
01-06-2013
Publisher
Springer India
Published in
Hepatology International / Issue 2/2013
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-012-9402-3

Other articles of this Issue 2/2013

Hepatology International 2/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.